Read more here
Read more here
Read more here

Chronic Nephropathies

Chronic Nephropathies - DiaPat® RenOM Test

Diagnosis of chronic kidney disease is established at a late stage, when substantial organ damage occurred. The analysis of the urine proteome through the DiaPat® RenOM Test enables detecting chronic kidney diseases (CKD) at a very early stage with an accuracy of >85%.

Differential diagnosis

The differential diagnosis of most kidney diseases normally requires a renal biopsy. Due to the considerable risks and adverse side-effects of this surgical procedure, biopsy is carried out at a hospital.

The DiaPat®-RenOM test enables differential diagnosis of CKD, supersedes hospitalisation and avoids side-effects. This is particular helpful, whenever kidney biopsy is associated with great risks, this applies especially for children (avoiding anaesthetics), patients with only one kidney, or a deformed kidney (e.g. horse shoe kidney) or transplanted kidney as well as patients with an increased risk of bleeding. The test is a highly valuable complement of routine diagnostics facilitating the evaluation of the necessity for kidney biopsy.


Advantages of the DiaPat® tests

  • Painless (from urine)
  • Riskless sampling
  • Reliable (highly reliable detection of CKD with >85% accuracy)
  • Long-term (monitoring therapy success and individually adapted treatment)

In addition to the detection of CKD, at present, the DiaPat® RenOM Test enables differentiation between the following renal diseases:

1. Minimal Change Disease (MCD)
2. Membranous Glomerulonephritis (MNGN)
3. Focal Segmental Glomerulosclerosis (FSGS)
4. Immunoglobulin-A-Nephropathy (IgA-Nephropathy)
5. Lupus Nephritis (SLE)
6. Vasculitis

 Concerning diagnosis of Diabetic Nephropathy read more here.


Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.
Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.
J Am Soc Nephrol. 2015 Jan 14. pii: ASN.2014050423. [Epub ahead of print]


Gu YM, Thijs L, Liu YP, Zhang Z, Jacobs L, Koeck T, Zürbig P, Lichtinghagen R, Brand K, Kuznetsova T, Olivi L, Verhamme P, Delles C, Mischak H, Staessen JA.
The urinary proteome as correlate and predictor of renal function in a population study.
Nephrol Dial Transplant. 2014 Dec;29(12):2260-8. doi: 10.1093/ndt/gfu234. Epub 2014 Jun 30.


Argilés A, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM, Mischak H.
CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis.
PLoS One. 2013 May 14;8(5):e62837. doi: 10.1371/journal.pone.0062837. Print 2013.


Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
PLoS One. 2013;8(1):e53016. doi: 10.1371/journal.pone.0053016. Epub 2013 Jan 10.


Herget-Rosenthal S, Metzger J, Albalat A, Bitsika V, Mischak H.
Proteomic biomarkers for the early detection of acute kidney injury.
Prilozi. 2012 Jul;33(1):27-48.

Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group.
Normal and pathologic concentrations of uremic toxins.
J Am Soc Nephrol. 2012 Jul;23(7):1258-70. Epub 2012 May 24.

Mullen W, Delles C, Mischak H; members of EuroKUP COST action.
Urinary proteomics in the assessment of chronic kidney disease.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):654-61.

Mischak H, Thongboonkerd V, Schanstra JP, Vlahou A
Renal and urinary proteomics.
Proteomics Clin Appl. 2011 Jun;5(5-6):211-3. doi: 10.1002/prca.201190031.

Zürbig P, Dihazi H, Metzger J, Thongboonkerd V, Vlahou A
Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications.
Proteomics Clin Appl. 2011 Jun;5(5-6):256-68. doi: 10.1002/prca.201000133. Epub 2011 May 18.      

Foucher C, Schiffer E, Mischak H, Ansquer JC, Wilbraham D
Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers
Proteomics Clinical Applications 2011

Good DM, Zürbig P, Argilés A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JHH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H , Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.
Mol Cell Proteomics. 2010 Nov;9(11):2424-37. Epub 2010 Jul 8.

Kistler A, Mischak H, Poster D, Dakna M, Wuthrich R, Serra A
Identification of a unique urinary biomarker profile in autosomal dominant polycystic kidney disease
Kidney Int. 2009 Jul;76(1):89-96

Mischak H, Massy ZA, Jankowski J
Proteomics and uremia and renal disease
Semin Dial. 2009 Jul-Aug;22(4):409-16.

Zürbig P, Decramer S, Dakna M, Jantos J, Good DM, Coon JJ, Bandin F, Mischak H, Bascands JL, Schanstra JP.
The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease.
Proteomics. 2009 Apr;9(8):2108-17

Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, Theodorescu D, Dakna M, Coon J, Mischak H
Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in ANCA associated Vasculitis
Mol Cell Proteomics. 2009 Oct;8(10):2296-307. Epub 2009 Jun 28.

Haubitz M, Mischak H, Julian BA, Novak J
Urinary Protein Patterns as a Diagnostic Tool for Patients with Immunoglobulin A Nephropathy
European Renal Disease - Touch Briefings 2008

Schiffer E, Mischak H, Vanholder RC
Exploring the uremic toxins using proteomic technologies
Contrib Nephrol. 2008, 160: 159-171

Zurbig P, Mischak H
Capillary electrophoresis coupled to mass spectrometry for biomarker discovery and diagnosis of kidney diseases
Contrib Nephrol. 2008, 160: 107-126

Raedler T, Wittke S, Jahn H, Kössler A, Mischak H, Wiedemann K
Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results
Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(3): 673-678

Julian BA, Wittke S, Novak J, Good D, Coon JJ, Kellmann M, Zurbig P, Schiffer E, Haubitz M, Moldoveanu Z, Calcatera S, Wyatt R, Sykora J, Sladkova E, Hes O, Mischak H, Mc Guire B
Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases
Electrophoresis 2007, 28(23): 4469-4483

Julian BA, Wittke S, Haubitz M, Zurbig P, Schiffer E, McGuire BM, Wyatt RJ, Novak J
Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases
World Journal of Urology 2007, 35(5): 467-476

Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, Jankowski J, Mischak H
Advances in urinary proteome analysis and biomarker discovery
J Am Soc Nephrol. 2007, 18(4): 1057-1071

Walden M, Wittke S, Mischak H, Vanholder RC
Proteomics of human dialysate and ultrafiltrate fluids yielded by renal replacement therapy
Thongboonkerd V (Ed.) 2006, Proteomics of Human Body Fluids: Principles, Methods, and Applications

Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy
Kidney Int. 2005, 67(6): 2313-2320

Hillman M, Mischak H
CE-MS as a Tool for Renal Disease Analysis and Biomarker Discovery Pace Setter
The worldwide newsletter for capillary electrophoresis (Beckman Coulter) 2005, 9(2): 1-5

Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC
Proteomics: a novel tool to unravel the patho-physiology of uraemia
Nephrol Dial Transplant. 2004, 19(12): 3068-3077

Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, Golovko I, Rupprecht HD, Haubitz M, Hecker H, Mischak H, Fliser D
Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes
Kidney Int. 2004, 65(6): 2426-2434

Haubitz M, Fliser D, Haller H
Proteomanalyse – eine neue Perspektive für die klinische Diagnostik
Deutsches Ärzteblatt 2004, 101(21): A-1514 / B-1255 / C-1207

Weissinger EM, Mischak H
Proteom analysis applied towards early diagnosis of renal diseases and transplant-monitoring
Transplantationsmedizin 2004, 16: 2-9


Background information:

Chronic kidney disease (CKD) and renal damage is characterized by a slow, progressive loss of renal function over a period of months or years that finally leads to end-stage renal disease (ESRD). Patients with ESRD require renal replacement therapy (dialysis and/or kidney transplantation). The most common causes of chronic kidney disease in North America, Europe, and Japan are diabetic nephropathy, hypertension, and glomerulonephritis. Together, these diseases account for approximately 75% of all adult cases of ESRD.

Historically, kidney diseases were classified according to the anatomical compartment of the kidney that is involved. Glomerular diseases comprise a diverse group of histologically defined glomerulopathies, e.g. focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MGN), minimal change disease (MCD), IgA nephropathy (IgAN), diabetic nephropathy (DN) or systemic lupus erythematosus (SLE).

In clinical practice, renal damage associated to CKD is generally detected by proteinuria and/or changes in serum creatinine for estimation of glomerular filtration rate. However, there are major limitations to the use of both methods, as they are quite imprecise and a generally late sign of renal damage. In some cases, however, kidney biopsy for histological analysis is necessary to decide on therapeutic measures.



Facebook teilen Twittern
>> Share and recommend our page <<